Antonis A. Manolis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonis A. Manolis has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Antonis Stavros Manolis
First Department of Cardiology, Athens University School of Medicine, Athens, Greece
9 shared publications - Theodora A. Manolis
Department of Psychiatry, Eginiteio UniversityHospital, Athens, Greece
8 shared publications Apostolos Vouliotis
School of Medicine, Athens University, Athens, Greece
3 shared publicationsTheodora A. Manolis
Department of Psychiatry,Aiginiteio University Hospital, Athens, Greece
2 shared publicationsAntonis S. Manolis
First Department of Cardiology, Ippokrateio University Hospital, Athens University School of Medicine, Athens, Greece
1 shared publication- Apostolos Ilias Vouliotis
Department of Cardiology, Euroclinic Hospital, Athens, Greece
1 shared publication
Latest Publications
- 3 July 2026
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 24, 1-33
Steps to Walk Out of, or Side Track, Cardiovascular Disease to Achieve Longevity
Aging is a relentless process of gradual physio-biochemical non-reversible deterioration that significantly influences human health, leading to declining cellular function and increasing cellular damage; it is recognized as a major risk factor for atherosclerosis and cardiovascular (CV) disease (CVD), the leading cause of death worldwide. Although aging is inevitable, healthy aging is the key to well-being. Longevity is a desirable yet complex outcome influenced by a wide range of factors, including genetics, lifestyle choices, healthcare access, socio-economic conditions, and other environmental factors. The compromised efficiency of processes that counteract age-associated molecular damage affects CVD susceptibility and expedites the emergence of clinical disease. Recently recognized key resilience mechanisms related to aging may constitute new potential therapeutic targets. Geroscience focuses on the discovery and translation of methods and interventions to curtail or reverse age-related deficits that compromise quality of life for older individuals. The geroscience paradigm, increasingly acknowledged in medical specialties, renders possible the prevention of premature aging, the optimal treatment of geriatric diseases, the reduction of healthcare disparities and prejudices, and the extension of the population's health span. These important geroscience issues, including multimorbidity, frailty, tendency to frequent falls, cognitive and multisensory impairment, cardiac arrhythmias, coronary disease and heart failure, as well as undernutrition, sarcopenia and polypharmacy, are herein discussed, together with recent relevant medical advances. Emphasis is placed on boosting psychology and also on pharmacological and nonpharmacological interventions such as exercise and physical activity, healthy diets and lifestyle that target key components of aging, which might assist in both primary (geroprotection) and secondary prevention (gerotherapeutics) of CV and other diseases posing an enormous challenge in older age. The geroscience paradigm is increasingly recognized in medical specialties, enabling the prevention of premature aging, optimal management of geriatric ailments, reduction of health-care disparities and prejudices, and potential improvement of the population's health-span.
- 3 July 2026
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 24, 1-33
Steps to Walk Out of, or Side Track, Cardiovascular Disease to Achieve Longevity
Aging is a relentless process of gradual physio-biochemical non-reversible deterioration that significantly influences human health, leading to declining cellular function and increasing cellular damage; it is recognized as a major risk factor for atherosclerosis and cardiovascular (CV) disease (CVD), the leading cause of death worldwide. Although aging is inevitable, healthy aging is the key to well-being. Longevity is a desirable yet complex outcome influenced by a wide range of factors, including genetics, lifestyle choices, healthcare access, socio-economic conditions, and other environmental factors. The compromised efficiency of processes that counteract age-associated molecular damage affects CVD susceptibility and expedites the emergence of clinical disease. Recently recognized key resilience mechanisms related to aging may constitute new potential therapeutic targets. Geroscience focuses on the discovery and translation of methods and interventions to curtail or reverse age-related deficits that compromise quality of life for older individuals. The geroscience paradigm, increasingly acknowledged in medical specialties, renders possible the prevention of premature aging, the optimal treatment of geriatric diseases, the reduction of healthcare disparities and prejudices, and the extension of the population's health span. These important geroscience issues, including multimorbidity, frailty, tendency to frequent falls, cognitive and multisensory impairment, cardiac arrhythmias, coronary disease and heart failure, as well as undernutrition, sarcopenia and polypharmacy, are herein discussed, together with recent relevant medical advances. Emphasis is placed on boosting psychology and also on pharmacological and nonpharmacological interventions such as exercise and physical activity, healthy diets and lifestyle that target key components of aging, which might assist in both primary (geroprotection) and secondary prevention (gerotherapeutics) of CV and other diseases posing an enormous challenge in older age. The geroscience paradigm is increasingly recognized in medical specialties, enabling the prevention of premature aging, optimal management of geriatric ailments, reduction of health-care disparities and prejudices, and potential improvement of the population's health-span.
- 18 June 2026
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 24, 1-32
Mast Cells and Cardiovascular Disorders
Mastocytosis is a neoplasm characterised by clonal proliferation of mast cells (MCs) in the skin and other organs, including the heart, and symptoms produced by MC-derived mediators. MC activation syndrome (MCAS) relates to increased and inappropriate activation of MCs without clonal proliferation. Mast cells are tissue-resident immune cells strategically located in different cardiac sites, e.g., myocardium, pericardium, aortic valve, and close to nerves, and in atherosclerotic plaques. The mediators (e.g., histamine, tryptase, chymase, cytokines, and chemokines) have roles in inflammation, angiogenesis, tissue remodelling, and fibrosis. They activate different cardiac resident immune cells (e.g., macrophages) and structural cells (e.g., fibroblasts and endothelial cells). MCs participate in atherosclerosis and several cardiovascular diseases (CVD), comprising allergic angina, coronary syndromes, and arrhythmias, by destabilizing and promoting atherosclerotic plaque rupture with its attendant dire consequences. Furthermore, MCs stimulate fibrosis after a myocardial infarction. MCAS is increasingly appreciated as it affects many patients previously noted to have various apparently idiopathic chronic multisystem inflammatory and/or allergic diseases or dystrophisms. Symptoms resulting from mediator release comprise flushing, hypotension, urticaria, angioedema, headache, vomiting, and diarrhea. Diagnosis is rendered by skin and/or bone marrow biopsy. Considering the increasing incidence and prevalence of MC-related diseases, guidance is needed for clinicians or researchers to select efficacious MC stabilizers that could block external stimulus signals into cells, inhibit intracellular signalling pathways, and disrupt degranulation. These novel therapies may soon find their way into the clinical arena. All relevant data and important advances in this recently recognized clinical entity are herein reviewed.
- 18 June 2026
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 24, 1-32
Mast Cells and Cardiovascular Disorders
Mastocytosis is a neoplasm characterised by clonal proliferation of mast cells (MCs) in the skin and other organs, including the heart, and symptoms produced by MC-derived mediators. MC activation syndrome (MCAS) relates to increased and inappropriate activation of MCs without clonal proliferation. Mast cells are tissue-resident immune cells strategically located in different cardiac sites, e.g., myocardium, pericardium, aortic valve, and close to nerves, and in atherosclerotic plaques. The mediators (e.g., histamine, tryptase, chymase, cytokines, and chemokines) have roles in inflammation, angiogenesis, tissue remodelling, and fibrosis. They activate different cardiac resident immune cells (e.g., macrophages) and structural cells (e.g., fibroblasts and endothelial cells). MCs participate in atherosclerosis and several cardiovascular diseases (CVD), comprising allergic angina, coronary syndromes, and arrhythmias, by destabilizing and promoting atherosclerotic plaque rupture with its attendant dire consequences. Furthermore, MCs stimulate fibrosis after a myocardial infarction. MCAS is increasingly appreciated as it affects many patients previously noted to have various apparently idiopathic chronic multisystem inflammatory and/or allergic diseases or dystrophisms. Symptoms resulting from mediator release comprise flushing, hypotension, urticaria, angioedema, headache, vomiting, and diarrhea. Diagnosis is rendered by skin and/or bone marrow biopsy. Considering the increasing incidence and prevalence of MC-related diseases, guidance is needed for clinicians or researchers to select efficacious MC stabilizers that could block external stimulus signals into cells, inhibit intracellular signalling pathways, and disrupt degranulation. These novel therapies may soon find their way into the clinical arena. All relevant data and important advances in this recently recognized clinical entity are herein reviewed.
- 16 June 2026
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 24, 1-33
Occupational and Environment-Related Cardiovascular Disease: A Comprehensive Review of the Literature
Work is a social determinant of Cardiovascular (CV) and general health and can both influence and be influenced by health. The type of work, working conditions, and work environment are fundamental social determinants of CV and general health status. Climate change presents an urgent and increasing threat to workers' health, via both direct exposure to environmental risks and the indirect worsening of social and health inequalities. Occupational health, which focuses on the promotion of mental and physical health and well-being of workers, and the avoidance of occupationrelated health risks, is a crucial but less discussed concern and component of human health. Relevant research at the intersection of climate change and occupational health remains scarce. Additionally, mitigation of climate change and adaptation efforts are driving forces for rapid transformations in the workplace, including shifts towards sustainability and circular economy models. These transitions are creating new occupational hazards, including those concerning renewable energy and the circular economy sectors. Investment in occupational health research and surveillance should be increased to address the evolving influences of both climate change and the green transition, to enhance and protect workers' CV and general health. Among the work-related factors that play an important role in patients with CVD, the following seem crucial: work participation, physical and mental work capability, appropriate work, support from and flexibility of the work environment, inter-personal communication, person-centered milieu, and interdisciplinary communication. A moderate leisure-time physical activity combined with moderate occupational physical activity may be a more plausible way to combine these two activities to sustain and/or improve CV health. Such an approach may be able to ameliorate workrelated outcomes in patients with CVD. Finally, lifestyle interventions targeting multiple behaviors are also most important to prevent CVD and attain cardiometabolic health. All these issues of occupational CVD are herein reviewed, and relevant meta-analyses are tabulated and discussed.
- 16 June 2026
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 24, 1-33
Occupational and Environment-Related Cardiovascular Disease: A Comprehensive Review of the Literature
Work is a social determinant of Cardiovascular (CV) and general health and can both influence and be influenced by health. The type of work, working conditions, and work environment are fundamental social determinants of CV and general health status. Climate change presents an urgent and increasing threat to workers' health, via both direct exposure to environmental risks and the indirect worsening of social and health inequalities. Occupational health, which focuses on the promotion of mental and physical health and well-being of workers, and the avoidance of occupationrelated health risks, is a crucial but less discussed concern and component of human health. Relevant research at the intersection of climate change and occupational health remains scarce. Additionally, mitigation of climate change and adaptation efforts are driving forces for rapid transformations in the workplace, including shifts towards sustainability and circular economy models. These transitions are creating new occupational hazards, including those concerning renewable energy and the circular economy sectors. Investment in occupational health research and surveillance should be increased to address the evolving influences of both climate change and the green transition, to enhance and protect workers' CV and general health. Among the work-related factors that play an important role in patients with CVD, the following seem crucial: work participation, physical and mental work capability, appropriate work, support from and flexibility of the work environment, inter-personal communication, person-centered milieu, and interdisciplinary communication. A moderate leisure-time physical activity combined with moderate occupational physical activity may be a more plausible way to combine these two activities to sustain and/or improve CV health. Such an approach may be able to ameliorate workrelated outcomes in patients with CVD. Finally, lifestyle interventions targeting multiple behaviors are also most important to prevent CVD and attain cardiometabolic health. All these issues of occupational CVD are herein reviewed, and relevant meta-analyses are tabulated and discussed.
- 8 May 2026
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 24, 1-21
The Use of Colchicine in Cardiovascular Disease: Anti-Inflammatory Mechanisms and Clinical Utility
Current data indicate that low-dose colchicine (0.5 mg/day) may reduce the risk of major adverse cardiovascular (CV) events (MACE) in patients with coronary artery disease and thus can become a new standard, effective, cost-efficient, and well-tolerated therapy for cardiac patients. Various important randomised controlled studies have reported on colchicine's influence on CV outcomes, and meta-analyses of these trials show that colchicine mitigates the risk of recurrent MACE by 25%, resulting in its recent approval by the Food and Drug Administration for the management and prevention of CV disease (CVD). While colchicine reduces MACE risk, its survival benefit remains inconclusive, warranting further long-term investigations. The non-significant decrease in CV death of ~20% is surpassed by a more apparent, borderline non-significant rise in the risk of non-CV death by ~40%. Main populations comprising patients with heart failure, patients submitted to surgical revascularisation, females, elderly persons, and non-Caucasians are under-represented in current trials, limiting the generalisability of such treatment. Thus, colchicine shows promise in curtailing MACE, additional data from large-scale, long-term trials are needed to corroborate such findings before its widespread use in clinical practice to favourably influence the secondary prevention of atherosclerotic CVD. Colchicine may have important advantages in curtailing myocardial infarction in specific high-risk patient groups but uncertainty about the magnitude of the impact on survival remains, particularly in the general population. Unfortunately, this agent is plagued by gastrointestinal side effects, which may deter its use. More data from larger-scale randomised studies will be required.
- 8 May 2026
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 24, 1-21
The Use of Colchicine in Cardiovascular Disease: Anti-Inflammatory Mechanisms and Clinical Utility
Current data indicate that low-dose colchicine (0.5 mg/day) may reduce the risk of major adverse cardiovascular (CV) events (MACE) in patients with coronary artery disease and thus can become a new standard, effective, cost-efficient, and well-tolerated therapy for cardiac patients. Various important randomised controlled studies have reported on colchicine's influence on CV outcomes, and meta-analyses of these trials show that colchicine mitigates the risk of recurrent MACE by 25%, resulting in its recent approval by the Food and Drug Administration for the management and prevention of CV disease (CVD). While colchicine reduces MACE risk, its survival benefit remains inconclusive, warranting further long-term investigations. The non-significant decrease in CV death of ~20% is surpassed by a more apparent, borderline non-significant rise in the risk of non-CV death by ~40%. Main populations comprising patients with heart failure, patients submitted to surgical revascularisation, females, elderly persons, and non-Caucasians are under-represented in current trials, limiting the generalisability of such treatment. Thus, colchicine shows promise in curtailing MACE, additional data from large-scale, long-term trials are needed to corroborate such findings before its widespread use in clinical practice to favourably influence the secondary prevention of atherosclerotic CVD. Colchicine may have important advantages in curtailing myocardial infarction in specific high-risk patient groups but uncertainty about the magnitude of the impact on survival remains, particularly in the general population. Unfortunately, this agent is plagued by gastrointestinal side effects, which may deter its use. More data from larger-scale randomised studies will be required.
- 17 March 2026
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 24, 1-26
Chronic Obstructive Pulmonary Disease and Cardiovascular Disorders
Chronic obstructive pulmonary disease (COPD) remains a significant global public health challenge, plagued by substantial morbidity and mortality worldwide; it is one of the main causes of death worldwide, especially during episodes of severe exacerbation. There is a higher COPD burden noted in regions with high smoking prevalence, air pollution, and faster socioeconomic development. There is also a high number of cardiovascular (CV) comorbidities among these patients, pointing to a need for routine CV screening in such circumstances. These two diseases, COPD and CV disease (CVD), are associated via an intricate and multifactorial interplay characterized by convergent risk factors, systemic inflammation, and interlinked pathophysiological mechanisms, with atherosclerosis being a principal inflammatory process linking these two disorders, driven by systemic inflammation, oxidative stress, and endothelial dysfunction. Importantly, despite the fact that CVD is common in COPD, it remains underdiagnosed and undertreated due to overlapping respiratory and cardiac symptomatology. The latter issue is accentuated in the case of heart failure (HF) and coronary artery disease (CAD), whereby HF atypical symptoms may mimic the clinical picture of COPD exacerbation and CAD presenting with atypical symptomatology such as dyspnea on exertion and/or fatigue, which may point to HF/COPD worsening. Thus, a structured CV assessment and management following exacerbations of COPD is needed in order to identify CAD and/or other new heart disease in these patients and guide appropriate management. These issues are discussed with relevant metaanalyses and key guidelines tabulated, and the involved interrelated mechanisms are pictorially illustrated.
- 17 March 2026
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 24, 1-26
Chronic Obstructive Pulmonary Disease and Cardiovascular Disorders
Chronic obstructive pulmonary disease (COPD) remains a significant global public health challenge, plagued by substantial morbidity and mortality worldwide; it is one of the main causes of death worldwide, especially during episodes of severe exacerbation. There is a higher COPD burden noted in regions with high smoking prevalence, air pollution, and faster socioeconomic development. There is also a high number of cardiovascular (CV) comorbidities among these patients, pointing to a need for routine CV screening in such circumstances. These two diseases, COPD and CV disease (CVD), are associated via an intricate and multifactorial interplay characterized by convergent risk factors, systemic inflammation, and interlinked pathophysiological mechanisms, with atherosclerosis being a principal inflammatory process linking these two disorders, driven by systemic inflammation, oxidative stress, and endothelial dysfunction. Importantly, despite the fact that CVD is common in COPD, it remains underdiagnosed and undertreated due to overlapping respiratory and cardiac symptomatology. The latter issue is accentuated in the case of heart failure (HF) and coronary artery disease (CAD), whereby HF atypical symptoms may mimic the clinical picture of COPD exacerbation and CAD presenting with atypical symptomatology such as dyspnea on exertion and/or fatigue, which may point to HF/COPD worsening. Thus, a structured CV assessment and management following exacerbations of COPD is needed in order to identify CAD and/or other new heart disease in these patients and guide appropriate management. These issues are discussed with relevant metaanalyses and key guidelines tabulated, and the involved interrelated mechanisms are pictorially illustrated.
- 1 January 2026
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 24 (1) , 20-32
Cardiovascular Disorders in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with multiorgan and system involvement, including the Cardiovascular (CV) system. Cardiac involvement in these patients is frequent and most often asymptomatic, at least in the early stages. It includes accelerated atherosclerosis, premature Coronary Artery Disease (CAD), and a high risk of CV complications. The risk of developing CV Disease (CVD) in SLE is linked not only with classical CV risk factors but also with disease-specific factors, like the degree of activity, autoantibodies, organ damage, and type of therapy. Clinical presentation comprises several clinical manifestations ranging from angina to acute Myocardial Infarction (MI) and Sudden Cardiac Death (SCD). The leading cause of death in SLE patients is from CVD due to accelerated atherosclerosis, which often has a more rapid progression compared with the general population. The CV risk in SLE is greater when antiphospholipid antibodies are present. Regarding diagnosis, apart from relevant blood tests, the simplest and readily available diagnostic test, echocardiography, with its contemporary techniques that include global longitudinal strain, is needed to provide a more thorough cardiac evaluation and allow for early management. These aspects of the disease, together with issues regarding phenotypes, biomarkers, neonatal lupus, heart block, SLE-related CV ailments such as coronary artery disease (CAD), myocarditis, valvular heart disease, and the antiphospholipid syndrome, as well as diagnostic modalities, drug and interventional therapies, and current relevant guidelines are all thoroughly reviewed and discussed in this article.
- 1 January 2026
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 24 (1) , 20-32
Cardiovascular Disorders in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with multiorgan and system involvement, including the Cardiovascular (CV) system. Cardiac involvement in these patients is frequent and most often asymptomatic, at least in the early stages. It includes accelerated atherosclerosis, premature Coronary Artery Disease (CAD), and a high risk of CV complications. The risk of developing CV Disease (CVD) in SLE is linked not only with classical CV risk factors but also with disease-specific factors, like the degree of activity, autoantibodies, organ damage, and type of therapy. Clinical presentation comprises several clinical manifestations ranging from angina to acute Myocardial Infarction (MI) and Sudden Cardiac Death (SCD). The leading cause of death in SLE patients is from CVD due to accelerated atherosclerosis, which often has a more rapid progression compared with the general population. The CV risk in SLE is greater when antiphospholipid antibodies are present. Regarding diagnosis, apart from relevant blood tests, the simplest and readily available diagnostic test, echocardiography, with its contemporary techniques that include global longitudinal strain, is needed to provide a more thorough cardiac evaluation and allow for early management. These aspects of the disease, together with issues regarding phenotypes, biomarkers, neonatal lupus, heart block, SLE-related CV ailments such as coronary artery disease (CAD), myocarditis, valvular heart disease, and the antiphospholipid syndrome, as well as diagnostic modalities, drug and interventional therapies, and current relevant guidelines are all thoroughly reviewed and discussed in this article.
- 22 August 2025
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 23 (2) , 1-15
Significant Stagnancy in the Search and Use of New Antiarrhythmic Agents With Some Recent Beams of Hope
Over the last few decades, there has been noteworthy long-lasting stagnancy in the field of antiarrhythmic drugs (AAD), with the development of novel AAD notably declining over the years. Although ablation therapy has dominated, there remains an unmet need for effective and safe antiarrhythmic therapy in those choosing a conservative approach and those failing the ablation procedure( s). Also, in patients with life-threatening ventricular arrhythmias, in the era of the implantable cardioverter defibrillator dominance, many patients require effective and safe AAD therapy to mitigate the recurrence of arrhythmias and the delivery of painful and unpleasant device shocks. The repurposing and reformulation of current drugs in circulation for novel therapeutic uses may provide new avenues for developing antiarrhythmic treatments that can assist in curtailing cardiac arrhythmia- associated morbidity and mortality, and ameliorate the quality of life for millions of patients. Stressful factors may lead to endothelial dysfunction and a surge in blood pressure, contributing to the emergence of cardiac arrhythmogenic effects, including myocardial fibrosis and remodeling of structural, ion channels, and connexin 43 channels, with consequent dysfunction. Agents influencing this latter protein may have cardioprotective and potentially antiarrhythmic effects. In this review of new antiarrhythmic agents, the advantages of sodium-glucose co-transporter inhibitors, and also those of pirfenidone, ranolazine, sotatercept, mirabegron, nintedanib, and melatonin are discussed. Some of these agents have been approved for other indications and repurposed for use in managing arrhythmias. Finding novel antiarrhythmic therapeutic approaches may be challenging for further research.
- 22 August 2025
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 23 (2) , 1-15
Significant Stagnancy in the Search and Use of New Antiarrhythmic Agents With Some Recent Beams of Hope
Over the last few decades, there has been noteworthy long-lasting stagnancy in the field of antiarrhythmic drugs (AAD), with the development of novel AAD notably declining over the years. Although ablation therapy has dominated, there remains an unmet need for effective and safe antiarrhythmic therapy in those choosing a conservative approach and those failing the ablation procedure( s). Also, in patients with life-threatening ventricular arrhythmias, in the era of the implantable cardioverter defibrillator dominance, many patients require effective and safe AAD therapy to mitigate the recurrence of arrhythmias and the delivery of painful and unpleasant device shocks. The repurposing and reformulation of current drugs in circulation for novel therapeutic uses may provide new avenues for developing antiarrhythmic treatments that can assist in curtailing cardiac arrhythmia- associated morbidity and mortality, and ameliorate the quality of life for millions of patients. Stressful factors may lead to endothelial dysfunction and a surge in blood pressure, contributing to the emergence of cardiac arrhythmogenic effects, including myocardial fibrosis and remodeling of structural, ion channels, and connexin 43 channels, with consequent dysfunction. Agents influencing this latter protein may have cardioprotective and potentially antiarrhythmic effects. In this review of new antiarrhythmic agents, the advantages of sodium-glucose co-transporter inhibitors, and also those of pirfenidone, ranolazine, sotatercept, mirabegron, nintedanib, and melatonin are discussed. Some of these agents have been approved for other indications and repurposed for use in managing arrhythmias. Finding novel antiarrhythmic therapeutic approaches may be challenging for further research.
- 1 May 2025
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 23 (3) , 172-195
Emotional Stress in Cardiac and Vascular Diseases
Introduction/Objective: Emotional, mental, or psychological distress, defined as increased symptoms of depression, anxiety, and/or stress, is common in patients with chronic diseases, such as cardiovascular (CV) disease (CVD). Methods: Literature was reviewed regarding data from studies and meta-analyses examining the impact of emotional stress on the occurrence and outcome of several CVDs (coronary disease, heart failure, hypertension, arrhythmias, stroke). These influences' pathophysiology and clinical spectrum are detailed, tabulated, and pictorially illustrated. Results: This type of stress is a newly recognized risk and prognosticator for CVD including coronary artery disease, heart failure, hypertension, cardiac arrhythmias, and stroke, independently of conventional risk factors. It can impact CV outcomes, and also affect health care utilization, with more patient visits to health care facilities. The biological systems activated by mental stress comprise the sympathetic nervous system (SNS), the renin-angiotensin system (RAS), and the hypothalamic- pituitary-adrenal (HPA) axis, while several other biological processes are disrupted, such as endothelial function, inflammatory responses, oxidative stress, mitochondrial function and the function of the amygdala which is the central nervous system processing center of emotions and emotional reactions. Conclusion: Emotional stress that aggravates symptoms of depression, anxiety, and/or perceived mental stress is common in patients with chronic diseases, such as CVD. It is a newly recognized risk and prognosticator for several CVDs. It can influence CV outcomes, and also affect health care utilization. The biological systems activated by mental stress comprise the SNS, the RAS, and the HPA axis, while several other biological processes are disrupted.
- 1 May 2025
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 23 (3) , 172-195
Emotional Stress in Cardiac and Vascular Diseases
Introduction/Objective: Emotional, mental, or psychological distress, defined as increased symptoms of depression, anxiety, and/or stress, is common in patients with chronic diseases, such as cardiovascular (CV) disease (CVD). Methods: Literature was reviewed regarding data from studies and meta-analyses examining the impact of emotional stress on the occurrence and outcome of several CVDs (coronary disease, heart failure, hypertension, arrhythmias, stroke). These influences' pathophysiology and clinical spectrum are detailed, tabulated, and pictorially illustrated. Results: This type of stress is a newly recognized risk and prognosticator for CVD including coronary artery disease, heart failure, hypertension, cardiac arrhythmias, and stroke, independently of conventional risk factors. It can impact CV outcomes, and also affect health care utilization, with more patient visits to health care facilities. The biological systems activated by mental stress comprise the sympathetic nervous system (SNS), the renin-angiotensin system (RAS), and the hypothalamic- pituitary-adrenal (HPA) axis, while several other biological processes are disrupted, such as endothelial function, inflammatory responses, oxidative stress, mitochondrial function and the function of the amygdala which is the central nervous system processing center of emotions and emotional reactions. Conclusion: Emotional stress that aggravates symptoms of depression, anxiety, and/or perceived mental stress is common in patients with chronic diseases, such as CVD. It is a newly recognized risk and prognosticator for several CVDs. It can influence CV outcomes, and also affect health care utilization. The biological systems activated by mental stress comprise the SNS, the RAS, and the HPA axis, while several other biological processes are disrupted.
- Open Access
- 1 January 2025
- Published by XMLink in International Journal of Arrhythmia
- Vol. 26 (1)
Permanent parahisian pacing is feasible, effective and more physiologic: no more right ventricular apical pacing and no compulsive need for elaborate His bundle pacing
Manolis AA, et al. Int J Arrhythm. 2025 Sep;26:e6. https://doi.org/10.18501/ija.2025.26.e6
- 1 January 2025
- Published by XMLink in International Journal of Arrhythmia
- Vol. 26 (1)
Open AccessPermanent parahisian pacing is feasible, effective and more physiologic: no more right ventricular apical pacing and no compulsive need for elaborate His bundle pacing
Manolis AA, et al. Int J Arrhythm. 2025 Sep;26:e6. https://doi.org/10.18501/ija.2025.26.e6
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 23 (1) , 31-44
Current Strategies for Atrial Fibrillation Prevention and Management: Taming the Commonest Cardiac Arrhythmia
Atrial fibrillation (AF) is the commonest cardiac arrhythmia, constituting a major cause of morbidity and mortality, with an age-dependent incidence and prevalence ranging from 1-2% in the general population to ~10% in persons aged >60 years. The global prevalence of AF is rapidly increasing, mostly due to the aging population. If not properly and timely managed, this arrhythmia adversely affects left ventricular function, increases the risk of stroke five-fold, impairs quality of life, and shortens longevity. There is a genetic, hence non-modifiable, predisposition to the arrhythmia, while several life-style and cardiometabolic inciting factors, such as hypertension, heart failure, coronary disease, metabolic syndrome, alcohol use, and thyroid disorders, can be addressed, attesting to the importance of a holistic approach to its management. Thromboembolism is a serious consequence of AF, which could lead to a disabling stroke or have a lethal outcome. The risk of a thromboembolic complication can be estimated as based on a scoring system that takes into consideration the patient’s age, previous thromboembolic events, and clinical comorbidities. In addition, rapid AF could affect cardiac performance, leading to an elusive type of arrhythmia- induced cardiomyopathy and heart failure with grave consequences if undetected and untreated. Furthermore, AF may cause silent brain infarcts and/or its hemodynamic perturbations can account for a type of dementia that needs to be taken into account, emphasizing the need for AF screening and prevention strategies. All these issues are herein detailed, the causes of the arrhythmia are tabulated, and an algorithm illustrates our current approach to its management.
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 23 (1) , 31-44
Current Strategies for Atrial Fibrillation Prevention and Management: Taming the Commonest Cardiac Arrhythmia
Atrial fibrillation (AF) is the commonest cardiac arrhythmia, constituting a major cause of morbidity and mortality, with an age-dependent incidence and prevalence ranging from 1-2% in the general population to ~10% in persons aged >60 years. The global prevalence of AF is rapidly increasing, mostly due to the aging population. If not properly and timely managed, this arrhythmia adversely affects left ventricular function, increases the risk of stroke five-fold, impairs quality of life, and shortens longevity. There is a genetic, hence non-modifiable, predisposition to the arrhythmia, while several life-style and cardiometabolic inciting factors, such as hypertension, heart failure, coronary disease, metabolic syndrome, alcohol use, and thyroid disorders, can be addressed, attesting to the importance of a holistic approach to its management. Thromboembolism is a serious consequence of AF, which could lead to a disabling stroke or have a lethal outcome. The risk of a thromboembolic complication can be estimated as based on a scoring system that takes into consideration the patient’s age, previous thromboembolic events, and clinical comorbidities. In addition, rapid AF could affect cardiac performance, leading to an elusive type of arrhythmia- induced cardiomyopathy and heart failure with grave consequences if undetected and untreated. Furthermore, AF may cause silent brain infarcts and/or its hemodynamic perturbations can account for a type of dementia that needs to be taken into account, emphasizing the need for AF screening and prevention strategies. All these issues are herein detailed, the causes of the arrhythmia are tabulated, and an algorithm illustrates our current approach to its management.